JRJose Maria Reguera

Jose Maria Reguera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jose Maria Reguera has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort

    by Nerea Castillo-Fernández, Pedro María Martínez Pérez-Crespo, Elena Salamanca-Rivera, Laura Herrera-Hidalgo, Arístides de Alarcón, María Dolores Navarro-Amuedo, Teresa Marrodán Ciordia, María Teresa Pérez-Rodríguez, Juan Sevilla-Blanco, Alfredo Jover-Saenz, et al.

    It is not known whether sequential outpatient parenteral antimicrobial (OPAT) is as safe and effective as conventional hospitalization in patients with S. aureus bacteremia (SAB). A post-hoc analysis of the comparative effectiveness of conventional hospitalization versus sequential OPAT was performed in two prospective Spanish cohorts of patients with S. aureus bacteremia. The PROBAC cohort is a national, multicenter, prospective observational cohort of patients diagnosed in 22 Spanish hospitals between October 2016 and March 2017. The DOMUS OPAT cohort is a prospective observational cohort including patients from two university hospitals in Seville, Spain from 2012 to 2021. Multivariate regression was performed, including a propensity score (PS) for receiving OPAT, stratified analysis according to PS quartiles, and matched pair analyses based on PS. Four hundred and thirteen patients were included in the analysis: 150 in sequential OPAT and 263 in the full hospitalization therapy group. In multivariate analysis, including PS and center effect as covariates, 60-day treatment failure was lower in the OPAT group than in the full hospitalization group (p < 0.001; OR 0.275, 95%CI 0.129–0.584). In the PS-based matched analyses, sequential treatment under OPAT was not associated with higher 60-day treatment failure (p = 0.253; adjusted OR 0.660; % CI 0.324–1.345). OPAT is a safe and effective alternative to conventional in-patient therapy for completion of treatment in well-selected patients with SAB, mainly those associated with a low-risk source and without end-stage kidney disease.


  • Open Access

    Pseudomonas aeruginosa Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Development—Results from the PRO-BAC Cohort

    by Pedro María Martínez Pérez-Crespo, Álvaro Rojas, Joaquín Felipe Lanz-García, Pilar Retamar-Gentil, José María Reguera-Iglesias, Olalla Lima-Rodríguez, Alfonso del Arco Jiménez, Jonathan Fernández Suárez, Alfredo Jover-Saenz, Josune Goikoetxea Aguirre, et al.

    Community-onset bloodstream infections (CO-BSI) caused by gram-negative bacilli are common and associated with significant mortality; those caused by Pseudomonas aeruginosa are associated with worse prognosis and higher rates of inadequateempirical antibiotic treatment. The aims of this study were to describe the characteristics of patients with CO-BSI caused by P. aeruginosa, to identify predictors, and to develop a predictive score for P. aeruginosa CO-BSI. Materials/methods: PROBAC is a prospective cohort including patients >14 years with BSI from 26 Spanish hospitals between October 2016 and May 2017. Patients with monomicrobial P. aeruginosa CO-BSI and monomicrobial Enterobacterales CO-BSI were included. Variables of interest were collected. Independent predictors of Pseudomonas aeruginosa CO-BSI were identified by logistic regression and a prediction score was developed. Results: A total of 78patients with P. aeruginosa CO-BSI and 2572 with Enterobacterales CO-BSI were included. Patients with P. aeruginosa had a median age of 70 years (IQR 60–79), 68.8% were male, median Charlson score was 5 (IQR 3–7), and 30-daymortality was 18.5%. Multivariate analysis identified the following predictors of CO-BSI-PA [adjusted OR (95% CI)]: male gender [1.89 (1.14–3.12)], haematological malignancy [2.45 (1.20–4.99)], obstructive uropathy [2.86 (1.13–3.02)], source of infection other than urinary tract, biliary tract or intra-abdominal [6.69 (4.10–10.92)] and healthcare-associated BSI [1.85 (1.13–3.02)]. Anindex predictive of CO-BSI-PA was developed; scores ≥ 3.5 showed a negative predictive value of 89% and an area under the receiver operator curve (ROC) of 0.66. Conclusions: We did not find a good predictive score of P. aeruginosa CO-BSI due to its relatively low incidence in the overall population. Our model includes variables that are easy to collect in real clinical practice and could be useful to detect patients with very low risk of P. aeruginosa CO-BSI.


  • Open Access

    CLOT STIFFNESS MEASURED BY SEER SONORHEOMETRY AS A MARKER OF POOR PROGNOSIS IN HOSPITALIZED COVID-19 PATIENTS

    by Francisco José López-Jaime, Sandra Martín-Téllez, Alberto Doblas-Márquez, Ignacio Márquez-Gómez, José María Reguera-Iglesias, Manuel Isidro Muñoz-Pérez, Ihosvany Fernández-Bello, Adrián Montaño

    SUMMARY: Background: High incidence of life-threatening thrombotic complications is observed in severely ill COVID-19 patients. D-dimer may help evaluate disease severity and predict outcomes at hospital admission. However, its non-specificity and long analysis times strongly constrain its clinical value. Viscoelastic tests (VET) are widely available rapid point-of-care devices that have been shown to detect a hypercoagulable state (increased clot stiffness and fibrinolysis shutdown) as major contributors of the thrombotic complication in COVID-19. Nevertheless, based on the data obtained so far, definitive conclusions have not been drawn. Objectives: We aim to evaluate the association between VET parameters, standard coagulation tests and inflammation markers assessed in COVID-19 patients at hospital admission with disease severity and outcomes. Patients/Methods: A total of 69 COVID-19 patients requiring hospitalization were included in the study. The pro-inflammatory and pro-thrombotic state was analyzed by a panel of inflammation markers (IL-6, CRP, LDH, ferritin), routine coagulation tests (PT, aPTT, platelet count, fibrinogen, D-dimer) and a SEER sonorheometry VET profile (Quantra ® System). Results: Inflammatory markers IL-6, CRP, LDH and ferritin were elevated in a high percentage of patients (73.6%, 89.2%, 57.1% and 52.4%), as were coagulation-related parameters such as fibrinogen (81.4%) and D-dimer levels (66.2%). Quantra ® analysis revealed increased clot stiffness (CS) in 34.8%, particularly due to increased fibrinogen contribution (FCS) in 63.7%. Increased clot stability to lysis (CSL) was observed in 32.4%. Age > 65 years, elevated values of fibrinogen, D-dimer, LDH, increased clot stiffness and resistance to clot lysis were significantly associated with worsening disease. The Quantra ® FCS parameter showed a particularly high prognostic value in distinguishing patients with severe symptomatology. Conclusion: The global study of hemostasis by the whole blood point-of-care Quantra ® VET system may be a powerful tool for identifying poor prognosis in COVID-19 patients at hospital admission. In particular, FCS measured by Quantra ® could be established as a plausible prognostic marker to aid the clinical management of COVID-19 patients.

  • Open Access

    Clinical and immunoserological status 12 weeks after infection with COVID-19: prospective observational study

    by Lucia Valiente-De Santis, Ines Perez-Camacho, Beatriz Sobrino, Gracia Eugenia Gonzalez, Juan Diego Ruiz-Mesa, Antonio Plata, Ignacio Marquez-Gomez, Lidia Cobos, Marcial Delgado-Fernandez, Manuel Castano, et al.

    Objectives: to undertake a multidisciplinary follow-up at 12 weeks after an acute episode of COVID-19 to assess the functional status, persistence of symptoms and immunoserological situation. Methods: this prospective, observational, single-centre study included outpatients reviewed 12 weeks after an acute infection with SARS-CoV-2. The clinical evaluation included data about the acute episode and epidemiological and clinical variables. The patients were classified as symptomatic or asymptomatic depending on the persistence or otherwise of symptoms. All the patients underwent a full blood test and serology for SARS-CoV-2, as well as imaging tests and spirometry if needed. Results: The mean age of the 108 patients was 55.5 (SD: 15.4) years and 27.8% were health-care workers; 75.9% presented some type of symptoms, with dyspnoea being the most common. A D-dimer >500 ng/mL was detected in 32 (31.4%) patients. All the patients had antibodies against SARS-CoV-2. Being a health-care worker was associated with symptom persistence, with age ≥65 years being a protective factor. Conclusions: The persistence of symptoms in patents with COVID is usual 12 weeks after the acute episode, especially in patients <65 years and health-care workers. All our patients had developed antibodies by 12 weeks.


  • Open Access

    Brucella Endocarditis: Clinical, Diagnostic, and Therapeutic Approach

    by J. M. Reguera, F. Miralles, J. D. Colmenero, A. Alarcón, J. Pachón, C. Juárez

    Brucella endocarditis is an uncommon focal complication of brucellosis. Presented here are 11 cases of Brucella endocarditis, all managed uniformly. The median duration of symptoms prior to diagnosis was 3 months. Five patients (45%) had underlying valvular damage, and in six (55%) endocarditis involved a normal valve. There was a predominance of aortic involvement (82%) and a high incidence of left ventricular failure (91%). Diagnostic suspicion was essential in order to test blood cultures correctly, which in this series were positive in 63% of the patients. Surgical treatment was undertaken in eight patients (72%), all with aortic involvement and left ventricular failure impossible to control with medication. One patient died during the immediate postoperative period. All the other patients received antibiotic therapy for 3 months, with no signs of relapse of the infection or malfunction of the prosthesis during a minimum follow-up period of 24 months.


    • 1 February 1994
      • Vol. 12  (2) , 60-5

    [Evaluation of the Chromotitre EIA test in the diagnosis of human brucellosis].

    by J D Colmenero, J Porras, A Cárdenas, P Ocón, J M Reguera, M Delgado, J Sedeño

    The aim of the study was to evaluate the diagnostic efficacy of Chromotitre EIA test for the diagnosis of human brucellosis and compare the same with other classical serologic test. A prospective study was performed in 50 patients with active brucellosis. Thirty blood donors, 64 patients with different neoplastic and autoimmune infectious processes, 20 patients with history of brucellosis and 8 subjects with continuous exposure to Brucella at work were analyzed as the control group. Forty-five patients with brucellosis (90%) presented a positive IgM or IgG ELISA, 32 (62%) only IgM, 34 (68%) only IgG and 22 (44%) both immunoglobulins were positive. The sensitivity and specificity of ELISA test jointly evaluating IgM and IgG was 90 and 68%, respectively with these numbers being 62 and 98% and 68% and 38% for ELISA IgM and ELISA IgG. A moderate correlation was found between ELISA IgM with Bengal's Rose test (r = 0.53, p = 0.003) and sero-agglutination (r = 0.63, p = 0.0001) and ELISA IgG with the Coombs test (r = 0.55, p = 0.003). Only acceptable concordance was observed between ELISA IgM and sero-agglutination (kappa = 0.55, p = 0.0001). The ELISA test evaluated was very useful for the detection of IgM antibodies but was found to be insufficient with respect to IgG antibodies. Despite the slight diagnostic efficacy of the ELISA IgG the combined parallel use of both immunoglobulins achieved a performance similar to that achieved with the classical tests.


    • 1 June 1989
      • Vol. 7  (6) , 316-20

    [Combined use of rose Bengal and indirect immunofluorescence in the diagnosis of brucellosis].

    by J D Colmenero, J M Reguera, F P Cabrera, S Hernández, J Porras, P Manchado, M T Miranda

    In the present prospective study we have evaluated the sensitivity, specificity and predictive value of the Bengal rose and indirect immunofluorescence (IIF) in 122 patients with a bacteriological diagnosis of brucellosis. The sensitivity of the Bengal rose was 95.79% and its specificity 98.43%. IIF had a sensitivity of 68.80% and a specificity of 100% when the polyvalent anti-IgS conjugate was used. The combined parallel use of Bengal rose and IIF-IgS resulted in a sensitivity of 89.17% and a specificity of 100%. There was a good correlation between Bengal rose and serum agglutination test (r = 0.72); on the contrary, there were not good correlations between the fluorescent conjugates and Bengal rose, agglutination and Coombs test. In conclusion, the combined use of Bengal rose as a screening test and IIF as a confirmation study is a good diagnostic strategy for human brucellosis.